<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509806</url>
  </required_header>
  <id_info>
    <org_study_id>Ahead-G309</org_study_id>
    <nct_id>NCT02509806</nct_id>
  </id_info>
  <brief_title>Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of apatinib as maintenance
      therapy after first-line chemotherapy in Postoperative Recurrence / Metastasis Progressive
      Gastric Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will receive apatinib treatment(500mg qd p.o. q28d) until until disease
      progression or intolerable toxicity or patients withdrawal of consent after 4 cycles of DC
      first-line chemotherapy or only DC first-line chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>An expected average of 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib Maintenance Therapy After First-line Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib Mesylate Tablets 500 mg qd p.o. after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Intervention After First-line Chemotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Intervention after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib Mesylate Tablets 500 mg qd p.o.</description>
    <arm_group_label>Apatinib Maintenance Therapy After First-line Chemotherapy</arm_group_label>
    <other_name>ATAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18 to75 years old;

          2. Histologically proven progressive gastric cancer. All pts were received D2 gastrectomy
             and recurrence / metastasis occured;

          3. Complete 4 cycles DC first-line chemotherapy and no and no disease progression
             occurred. DC: Docetaxel 60-85mg/m2 iv d1, Cisplatin 60-75mg/m2 iv d1, q21d;

          4. ECOG PS of 0-1;

          5. Major organ function has to meet the following criteria:

             ANC ≥ 1.5 × 109 / L; HB ≥ 90g / L; PLT ≥ 100 × 109 / L; Bilirubin &lt;1.5 times the upper
             limit of normal (ULN); ALT and AST &lt;2.5 × ULN; liver metastases, if any, the ALT and
             AST&lt;5 × ULN;

          6. An expected survival of ≥ 3 months;

          7. Pregnancy test (serum or urine) has to be performed for woman of childbearing age
             within 7 days before enrolment and the test result must be negative. They shall take
             appropriate methods for contraception during the study until the 8th week post the
             last administration of study drug. For men, (previous surgical sterilization
             accepted), shall agree to take appropriate methods of contraception during the study
             until the 8th week post the last administration of study drug.

          8. Patient has to voluntarily join the study and sign the Informed Consent Form for the
             study;

        Exclusion Criteria:

          1. Confirmed that apatinib and/or its accessories allergy;

          2. Subjects with poor-controlled arterial hypertension (systolic blood pressure&gt; 140 mmHg
             and diastolic blood pressure &gt; 90 mm Hg) despite standard medical management; Coronary
             heart disease greater than ClassI; I-level arrhythmia (including QT interval
             prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class II cardiac
             dysfunction;

          3. Factors that could have an effect on oral medication (such as inability to swallow,
             chronic diarrhea and intestinal obstruction);

          4. Subjects with high gastrointestinal bleeding risk, including the following conditions:
             local active ulcer lesions with positive fecal occult blood test (++); history of
             black stool, or vomiting blood in the past 2 months;

          5. Abnormal Coagulation (INR&gt;1.5、APTT&gt;1.5 UNL), with tendency of bleed;

          6. Associated with CNS (central nervous system) metastases;

          7. Pregnant or lactating women;

          8. Pts with other malignant tumor within 5 years(except cured skin basal cell carcinoma
             and cervical carcinoma);

          9. With psychotropic drug abuse history and can't get rid of or mental disorder patients;

         10. Participated in other clinical trials within 4 weeks.

         11. Pts received VEGFR inhibitor treatment(i.e. sorafenib, sunitinib);

         12. Any other condition that might place the patient at undue risk or preclude a patient
             from completing the study;

         13. Other conditions regimented at investigators' discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhao Qun, MD</last_name>
    <phone>0311-86543035</phone>
    <email>zhaoqun516@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fourth Affiliated Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zhao Qun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2015</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Qun Zhao</investigator_full_name>
    <investigator_title>Principal Investgator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

